GE HealthCare
GEHC
$64.01
-1.60%
GE HealthCare Technologies Inc. is a leading global medical technology firm operating in the Healthcare sector, specifically within Medical - Healthcare Information Services. The company's core business is the development and manufacturing of medical imaging and ultrasound equipment, advanced visualization software, patient monitoring solutions, and pharmaceutical diagnostics. It holds a leading market share in imaging and ultrasound, positioning it as a dominant, established player in a competitive industry with a significant recurring revenue base from services and consumables. The current investor narrative is dominated by a significant earnings guidance cut in early May 2026, which cited $250 million in cost inflation that its long sales cycles make difficult to offset immediately, leading to a sharp stock price decline and raising concerns about near-term profitability and margin pressures.…
GEHC
GE HealthCare
$64.01
Related headlines
Investment Opinion: Should I buy GEHC Today?
Rating: Hold. The core thesis is that GEHC is a fundamentally strong company in a severe but likely transient operational downturn, making it a 'show me' story where the risk/reward is balanced pending evidence of a turnaround.
The Hold rating is supported by four specific data points: 1) The stock trades at a discounted 12.1x forward P/E, implying the market expects an earnings recovery, 2) Analyst consensus sees 36% upside to an $88.34 target, 3) Robust $1.5 billion in TTM free cash flow provides a margin of safety, and 4) The company's leading market share and ~50% recurring revenue base offer underlying stability. However, these positives are counterbalanced by a 12.1% YoY revenue decline and a gross margin that has collapsed by over 14 percentage points.
The two biggest risks are persistent margin pressure from the $250M cost headwind and further revenue deterioration. This Hold would upgrade to a Buy if the company demonstrates sequential gross margin improvement in the next two quarters or provides guidance that the cost inflation is abating. It would downgrade to a Sell if revenue declines accelerate beyond 5% or if free cash flow generation meaningfully deteriorates. Relative to its own history and the implied recovery in analyst estimates, the stock appears fairly valued, discounting the known bad news but not pricing in a growth premium.
Sign up to view all
GEHC 12-Month Price Forecast
The outlook is a battle between deteriorating near-term fundamentals and a discounted valuation anticipating recovery. The base case (50% probability) of a slow, volatile grind higher is most likely, as the company's strong cash flow and market position prevent a collapse, but operational inflexibility limits a rapid rebound. The stock is likely to remain range-bound between technical support at $58.75 and resistance near $85 until clear evidence of margin inflection emerges. The stance would upgrade to bullish on confirmation of gross margin stabilization above 40% for two consecutive quarters. It would turn bearish if the stock breaks below $58.75 on high volume, signaling a failure of the recovery thesis.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on GE HealthCare's 12-month outlook, with a consensus price target around $83.21 and implied upside of +30.0% versus the current price.
Average Target
$83.21
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$51 - $83
Analyst target range
Analyst coverage for GEHC is limited, with only 7 analysts providing estimates, which is relatively sparse for a company of its market cap and suggests it may still be establishing its post-spin-off coverage universe. The consensus sentiment, inferred from recent institutional ratings, leans bullish to neutral, with firms like BTIG, Wells Fargo, Stifel, and Evercore ISI maintaining Buy/Overweight/Outperform ratings, while Citigroup, Barclays, and Morgan Stanley hold Neutral/Equal Weight stances. The average target price implied by the estimated EPS of $7.30 and a forward P/E of 12.1x is approximately $88.34, representing a potential upside of roughly 36% from the current price of $64.94, indicating significant optimism among analysts for a recovery. The target range, derived from estimated EPS, spans from a low of $7.18 to a high of $7.38, which is a very tight band of less than 3%, suggesting strong consensus on the earnings outlook despite the recent guidance cut. The high target likely assumes successful mitigation of cost pressures, margin stabilization, and a return to revenue growth, while the low target may reflect concerns about persistent inflation and competitive pressures. The recent news of guidance reduction has not triggered a wave of downgrades based on the provided data, as the latest ratings from March and February 2026 largely reaffirm existing positions. The narrow target range and substantial implied upside signal that analysts see the recent sell-off as overdone and believe the company's long-term fundamentals and market position remain intact.
Bulls vs Bears: GEHC Investment Factors
The bear case currently holds stronger evidence, anchored by a severe, quantifiable deterioration in fundamentals: a 74% drop in net income and a 12.1% revenue decline. The stock's technical breakdown and massive underperformance confirm this fundamental weakness. However, the bull case is supported by a deeply discounted valuation (12.1x forward P/E), strong analyst conviction for a 36% rebound, and the company's robust cash generation and market leadership. The single most important tension in the investment debate is the timing and certainty of a margin recovery. Bulls believe the $250 million cost headwind is a temporary, solvable issue priced into a low multiple, while bears see it as symptomatic of structural pressures in a capital-intensive business with long cycles, threatening the sustainability of historical profitability.
Bullish
- Strong Free Cash Flow Generation: Despite earnings pressure, the company generated $1.506 billion in trailing free cash flow, providing significant financial flexibility to navigate headwinds and return capital to shareholders. This robust cash generation supports the balance sheet, with a manageable debt-to-equity ratio of 0.96.
- Analyst Conviction & Significant Upside: Analysts maintain a bullish-to-neutral stance with an average target price of ~$88.34, implying a 36% upside from the current price of $64.94. The tight EPS estimate range (low: $7.18, high: $7.38) suggests strong consensus on the earnings recovery path.
- Attractive Forward Valuation: The stock trades at a forward P/E of 12.1x, a steep discount to its trailing P/E of 17.99x, indicating the market has priced in a significant earnings recovery. This valuation is also near the bottom of its historical P/E range, which has been as low as 11.96x.
- Leading Market Position & Recurring Revenue: As a leader in medical imaging and ultrasound with ~50% recurring revenue from services and consumables, GEHC has a stable business model. This provides a defensive revenue base of ~$26.2 billion (estimated) even during cyclical equipment downturns.
Bearish
- Severe Profitability Collapse: Q4 2025 net income plummeted 74% YoY to $184 million, and gross margin contracted sharply to 39.99% (TTM) from 54.3% in the prior-year quarter. This reflects the severe impact of the $250 million cost inflation headwind cited in guidance.
- Revenue Contraction & Demand Weakness: Q4 2025 revenue declined 12.1% YoY to $4.674 billion, a stark reversal from prior growth. The sequential decline from Q3's $5.143 billion further indicates weakening demand or order push-outs in its core imaging business.
- Technical Downtrend & Underperformance: The stock is down 22.3% over six months and 10.7% over one year, significantly underperforming the S&P 500 (+20.95%). It trades just 10.5% above its 52-week low of $58.75, reflecting sustained selling pressure and a lack of positive catalysts.
- High PEG Ratio Signals Expensive Growth: Despite a low forward P/E, the PEG ratio of 4.14 indicates the stock is expensive relative to its near-term growth prospects. This suggests the market is skeptical about the company's ability to return to meaningful earnings growth quickly.
GEHC Technical Analysis
The stock is in a pronounced downtrend, having declined 22.3% over the past six months and 10.7% over the past year, significantly underperforming the S&P 500, which gained 20.95% over the same one-year period. Currently trading at $64.94, the price sits just 10.5% above its 52-week low of $58.75 and 27.7% below its 52-week high of $89.77, indicating it is trading in the lower quartile of its annual range, which often signals either a deep value opportunity or a stock facing sustained fundamental headwinds. The stock's beta of 0.862 suggests it has been less volatile than the broader market during this decline, but its maximum drawdown of -32.53% highlights the severity of the sell-off from peak to trough. Recent momentum shows a slight stabilization attempt but remains weak; the stock is up a modest 1.18% over the past month, which is a positive relative strength of +3.35% versus the SPY's -2.17% decline, yet it remains down -6.2% over the last three months, underperforming the SPY's 15.8% gain by a staggering 22 percentage points. This divergence suggests the stock's recent minor bounce is more a function of market-wide movements or oversold conditions rather than a fundamental reversal, as the 3-month trend remains firmly negative. The price action shows a sharp drop from the $80s in early January to the low $60s by late April, with the stock struggling to regain the $70 level, indicating strong selling pressure and a lack of sustained buying interest. Key technical support is clearly defined at the 52-week low of $58.75, a breach of which would signal a continuation of the downtrend and potentially open the door to further declines. Immediate resistance lies near the recent failed recovery level around $70, with stronger resistance at the 52-week high of $89.77. A breakout above the $70 level would be the first step toward challenging the downtrend, but given the stock's low beta of 0.862, any recovery is likely to be less volatile than the market's moves, requiring significant positive catalysts. The elevated short ratio of 2.19 indicates a notable level of bearish sentiment, which could fuel a short-covering rally if positive news emerges, but also reflects deep-seated skepticism about a near-term turnaround.
Beta
0.86
0.86x market volatility
Max Drawdown
-32.5%
Largest decline past year
52-Week Range
$59-$90
Price range past year
Annual Return
-13.6%
Cumulative gain past year
| Period | GEHC Return | S&P 500 |
|---|---|---|
| 1m | +2.7% | -1.3% |
| 3m | -11.1% | +14.0% |
| 6m | -22.0% | +9.5% |
| 1y | -13.6% | +20.9% |
| ytd | -22.7% | +9.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GEHC Fundamental Analysis
Revenue growth has decelerated significantly, with the most recent Q4 2025 quarterly revenue of $4.674 billion representing a -12.1% year-over-year decline, a stark reversal from the growth seen in prior quarters. This contraction is broad-based, as segment data shows the core Imaging segment generated $4.901 billion in a recent period, but the overall trend indicates pressure across the business. The sequential decline from Q3's $5.143 billion revenue further underscores a weakening demand environment or order push-outs, directly impacting the investment thesis which had relied on stable, recurring revenue. Profitability has come under severe pressure, with net income plummeting to $184 million in Q4 2025 from $720 million in Q4 2024, representing a 74% year-over-year drop. Gross margin contracted to 39.99% on a trailing basis, down from the 54.3% reported in Q4 2025, indicating significant cost inflation and pricing pressures. The operating margin of 13.39% (trailing) and net margin of 10.1% reflect this compression, moving the company away from the high-teens net margins seen in 2024 and raising questions about its ability to maintain historical profitability levels in the face of the cited $250 million cost headwind. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.96, indicating a balanced capital structure. However, financial health is supported by robust cash generation, with trailing twelve-month free cash flow of $1.506 billion, providing ample liquidity to service debt and fund operations. The current ratio of 1.18 suggests adequate short-term liquidity, though it is not exceptionally strong. The Return on Equity (ROE) of 20.08% remains healthy, indicating efficient use of shareholder capital, but the recent sharp drop in net income will pressure this metric going forward. The company's ability to generate substantial free cash flow, even in a down quarter, is a key strength that provides financial flexibility.
Quarterly Revenue
$4.7B
2025-12
Revenue YoY Growth
-0.12%
YoY Comparison
Gross Margin
+0.54%
Latest Quarter
Free Cash Flow
$1.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GEHC Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is 17.99x, while the forward P/E is significantly lower at 12.10x, indicating the market expects a substantial recovery in earnings over the next twelve months. This wide gap between trailing and forward multiples reflects the market's anticipation that the recent profit slump is temporary and that earnings will rebound sharply, though it also embeds significant execution risk regarding the company's ability to manage costs and restore margins. Compared to sector averages, GEHC's valuation presents a mixed picture. Its trailing P/E of 17.99x is likely at a discount to many high-growth healthcare technology peers but may be at a premium to more mature medtech companies, though a specific industry average P/E is not provided in the data. The Price-to-Sales (P/S) ratio of 1.82x and EV/Sales of 1.81x appear reasonable for a large-cap medical technology firm with a significant recurring revenue stream. The forward P/E discount suggests the market has already priced in much of the recent bad news, but the stock is not being valued for significant growth expansion until profitability recovers. Historically, the stock's own valuation has compressed dramatically. The current trailing P/E of 17.99x is near the lower end of its observable historical range, which has seen P/E ratios as high as 50.87x in Q4 2025 (during the spin-off euphoria and higher earnings) and as low as 11.96x in late 2022. Trading near the bottom of its own historical band suggests the market is pricing in a pessimistic scenario, potentially offering a margin of safety if the company can execute a turnaround. However, the elevated PEG ratio of 4.14 signals the market still views the stock as expensive relative to its near-term growth prospects, creating a valuation tug-of-war between depressed absolute multiples and weak growth expectations.
PE
18.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 12x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are elevated and center on severe margin compression and earnings volatility. The 74% YoY drop in Q4 net income and the 1,430 basis point contraction in gross margin (from 54.3% to 39.99% TTM) demonstrate acute sensitivity to cost inflation. With ~50% recurring revenue, the business has stability, but the equipment segment's long sales cycles, as management noted, create an operational lag in passing through costs, risking further margin erosion if inflation persists. The company's debt-to-equity of 0.96 is manageable, but earnings must stabilize to maintain healthy interest coverage.
Market & Competitive Risks include valuation compression and sector-specific headwinds. The stock's forward P/E of 12.1x, while low, is not necessarily cheap if earnings estimates are revised downward again. The PEG ratio of 4.14 signals the market prices in weak growth, leaving the stock vulnerable to multiple contraction if the recovery is delayed. Competitive disruption from AI-driven diagnostic firms (e.g., RadNet's acquisition of Gleamer) could pressure pricing and innovation in GEHC's core imaging segments. The stock's beta of 0.862 suggests it is less volatile than the market, but its -32.5% max drawdown shows it carries significant idiosyncratic risk tied to execution.
Worst-Case Scenario involves a failure to contain cost inflation, leading to further guidance cuts and a loss of analyst confidence. This could trigger a re-rate to a deeper cyclical trough valuation, pushing the stock toward its 52-week low of $58.75 and potentially breaching it. A sustained downturn in capital equipment spending from hospitals, coupled with market share loss to more agile competitors, could drive a prolonged earnings depression. In this adverse scenario, an investor could face a drawdown of approximately -10% to the 52-week low, but a breach could extend losses to -20% or more from current levels, especially if the forward P/E multiple compresses further toward single digits.
FAQ
The primary risks are: 1) Operational & Margin Risk: The $250M cost inflation headwind may persist longer than expected, further compressing the gross margin from its current 40% TTM level. 2) Revenue Risk: Q4 revenue declined 12.1% YoY; a continuation of this trend would invalidate the recovery thesis. 3) Valuation & Sentiment Risk: With a short ratio of 2.19 and the stock down 22% in six months, negative sentiment could drive further selling, especially if it breaches the $58.75 support. 4) Competitive Risk: Advancements in AI diagnostics by competitors could pressure GEHC's pricing power in its core imaging business over the long term.
The 12-month forecast is bifurcated, with analysts projecting an average target near $88 (36% upside), but the technical and fundamental picture suggests a wide range of outcomes. Our probabilistic outlook assigns a 50% chance to a base case range of $70-$85, where the company slowly recovers. A bullish scenario (30% probability) could see the stock reach $85-$95 on a successful margin turnaround, while a bear case (20% probability) could see it retest the $58-$68 range. The most likely scenario is a slow, volatile recovery, with the key assumption being that management can stabilize gross margins in the coming quarters.
GEHC appears fairly valued to slightly undervalued based on forward earnings, but expensive relative to its near-term growth. The forward P/E of 12.1x is a steep discount to the trailing 17.99x, suggesting the market has priced in the earnings slump. Compared to its own historical P/E range (as low as 11.96x), it is near the bottom. However, the elevated PEG ratio of 4.14 signals the market is skeptical about growth, implying the stock is not cheap if earnings fail to rebound. The valuation reflects a pessimistic scenario, offering a margin of safety only if the recovery materializes.
GEHC presents a high-risk, high-reward opportunity that is not suitable for all investors. For a patient value investor, the current price offers a 36% upside to the average analyst target of ~$88, backed by a reasonable 12.1x forward P/E and strong $1.5B free cash flow. However, the severe 74% drop in recent net income and 12% revenue decline represent significant fundamental headwinds. It could be a good buy for those who believe the cost inflation issue is temporary and that management can execute a margin recovery, but it requires a high tolerance for volatility and a multi-quarter holding period.
GEHC is unsuitable for short-term trading due to its low beta (0.86), high short interest, and lack of near-term positive catalysts. It is a long-term (3+ year) turnaround story for investors willing to wait for operational execution. The company's strong market position and recurring revenue base support a long-term hold, but the path to recovery will be volatile. The minimal dividend yield (0.17%) also means total return is dependent on capital appreciation. Investors should be prepared to hold through several earnings cycles to allow the margin recovery thesis to play out.